Enovis

Enovis ROCE

The Return on Capital Employed (ROCE) of Enovis (ENOV) as of Oct 27, 2026 is -1.26 %. In the previous year, Return on Capital Employed (ROCE) was -29.86 % — a change of -95.77% (higher).

ROCE

-1.26 %

YoY

-95.77%

Last updated:

In 2025, Enovis's return on capital employed (ROCE) was -1.26 %, a -95.77% increase from the -29.86 % ROCE in the previous year.

The Enovis ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
8.23 USD
Jan 1, 2019
4.87 USD
Jan 1, 2020
4.52 USD
Jan 1, 2021
-1.35 USD
Jan 1, 2022
-2.06 USD
Jan 1, 2023
-1.39 USD
Jan 1, 2024
-29.86 USD
Jan 1, 2025
-1.26 USD
The Enovis ROCE history
YEARROCEYoY
-1.26 %-95.77%
-29.86 %+2,056.18%
-1.39 %-32.87%
-2.06 %+53.15%
-1.35 %-129.78%
4.52 %-7.15%
4.87 %-40.78%
8.23 %+951.83%
0.78 %-89.84%
7.69 %-11.97%
8.74 %-28.45%
12.22 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Enovis Stock analysis

What does Enovis do? Enovis Corp. generates revenue through its two business segments, Prevention & Recovery and Reconstructive. The Prevention & Recovery segment sells rigid bracing products, orthopedic soft goods, vascular systems, compression garments, and hot and cold therapy products to clinical rehabilitation and sports medicine markets, including recovery sciences products like bone growth stimulators and electrical stimulators for pain management. The Reconstructive segment focuses on knee, hip, shoulder, elbow, foot, ankle, and finger implant products, surgical productivity solutions, and Novastep, a minimally invasive surgery (MIS) foot and ankle solution, targeting healthcare providers and surgical centers. Medical device manufacturers and healthcare institutions are the primary buyers of these products, with the company's solutions addressing both preventive care and reconstructive procedures. The company's product portfolio includes clinically differentiated medical devices designed for specific applications in reconstructive surgery, rehabilitation, pain management, and physical therapy. By manufacturing and distributing these products under its own brand, Enovis Corp. serves healthcare providers seeking innovative solutions for patient recovery and surgical efficiency. The Prevention & Recovery segment's offerings, such as compression garments and therapy products, cater to both clinical and sports medicine applications, while the Reconstructive segment's implants and surgical tools are used in orthopedic procedures worldwide. The company's focus on minimally invasive solutions like Novastep enhances its appeal to surgeons and hospitals looking to reduce patient recovery times. Enovis Corp. targets healthcare providers, surgical centers, and rehabilitation facilities as key customers for its medical devices. The Prevention & Recovery segment's products, including bone growth stimulators and electrical stimulators, are sold to clinical rehabilitation and sports medicine markets, while the Reconstructive segment's knee, hip, and foot implant products are distributed to orthopedic surgical centers. The company's revenue streams are derived from direct sales of these branded medical devices, with no mention of third-party partnerships or external distribution channels in the business description. Enovis is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Enovis's Return on Capital Employed (ROCE)

Enovis's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Enovis's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Enovis's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Enovis’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Enovis stock

Return on Capital Employed (ROCE) of Enovis is -1.26 % in 2025.

Return on Capital Employed (ROCE) of Enovis changed from -29.86 % to -1.26 %, representing a -95.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Enovis since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Enovis with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Enovis

All Key Metrics — Enovis